- Home
- EXK vs ETNB Comparison
EXK vs ETNB Comparison
Compare EXK & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXK
- ETNB
- Stock Information
- Founded
- EXK 1981
- ETNB 2018
- Country
- EXK Canada
- ETNB United States
- Employees
- EXK N/A
- ETNB N/A
- Industry
- EXK Precious Metals
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- EXK Basic Materials
- ETNB Health Care
- Exchange
- EXK Nasdaq
- ETNB Nasdaq
- Market Cap
- EXK 1.2B
- ETNB 1.0B
- IPO Year
- EXK N/A
- ETNB 2019
- Fundamental
- Price
- EXK $3.56
- ETNB $7.70
- Analyst Decision
- EXK Strong Buy
- ETNB Strong Buy
- Analyst Count
- EXK 3
- ETNB 9
- Target Price
- EXK $6.83
- ETNB $27.25
- AVG Volume (30 Days)
- EXK 12.0M
- ETNB 1.5M
- Earning Date
- EXK 05-13-2025
- ETNB 05-01-2025
- Dividend Yield
- EXK N/A
- ETNB N/A
- EPS Growth
- EXK N/A
- ETNB N/A
- EPS
- EXK N/A
- ETNB N/A
- Revenue
- EXK $217,639,000.00
- ETNB N/A
- Revenue This Year
- EXK $97.24
- ETNB N/A
- Revenue Next Year
- EXK $50.33
- ETNB N/A
- P/E Ratio
- EXK N/A
- ETNB N/A
- Revenue Growth
- EXK 5.93
- ETNB N/A
- 52 Week Low
- EXK $2.46
- ETNB $4.16
- 52 Week High
- EXK $5.67
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- EXK 46.23
- ETNB 53.47
- Support Level
- EXK $3.35
- ETNB $7.40
- Resistance Level
- EXK $3.67
- ETNB $8.92
- Average True Range (ATR)
- EXK 0.18
- ETNB 0.54
- MACD
- EXK -0.00
- ETNB 0.13
- Stochastic Oscillator
- EXK 45.65
- ETNB 53.88
About EXK Endeavour Silver Corporation (Canada)
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has two operating mining segments which are located in Mexico, Guanacevi and Bolanitos. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).